張宏
1.姓名、職稱等頭銜
張宏、研究員，博士生導(dǎo)師 zhanghong@shutcm.edu.cn
男，研究生學(xué)歷，理學(xué)博士，研究員，博士生導(dǎo)師。國家科技專家?guī)斐蓡T，上海市科學(xué)技術(shù)專家?guī)斐蓡T，國家自然科學(xué)基金評審專家，教育部學(xué)位與研究生教育發(fā)展中心評審專家， SCI期刊Current Pharmaceutical Design編委和Frontiers in Pharmacology客座編輯，Theranostics、International Journal of Biological Sciences、Phytomedicine、Phytotherapy Research、Journal of Ethnopharmacology等雜志審稿人。
長期從事組分中藥發(fā)現(xiàn)及配伍機(jī)制研究，主持完成的《疤痕止癢軟化膏防治增生性瘢痕的有效組分、作用機(jī)制及臨床療效》獲2015年度上海市浦東新區(qū)科技進(jìn)步二等獎。在此基礎(chǔ)上，進(jìn)一步提出基于成分配伍的組分中藥（成分中藥）研究策略（Journal of Ethnopharmacology, 2020, 254:112687. IF=5.195，2區(qū)，引用51次），并以抗腫瘤復(fù)方中成藥艾迪注射液為例進(jìn)行了示范性研究（Phytomedicine, 2022, 103:154231. IF=6.656，1區(qū)），為清楚闡釋方劑配伍理論的現(xiàn)代科學(xué)內(nèi)涵（中醫(yī)藥領(lǐng)域重大前沿科學(xué)問題之一）奠定了基礎(chǔ)。
先后主持承擔(dān)國家重點研發(fā)計劃、國家自然科學(xué)基金及上海市課題等20余項。第一完成人獲得上海市浦東新區(qū)科技進(jìn)步二等獎1項；授權(quán)發(fā)明專利11項；出版教材和專著，副主編4部，編委6部；發(fā)表論文150余篇，其中作為第一作者或通訊作者SCI論文82篇、核心期刊35篇，IF>5.0 SCI論文31篇，總引用4800余次，2篇入選ESI全球高被引論文；H指數(shù)39。
2.近五年以第一負(fù)責(zé)人承擔(dān)的科研課題與經(jīng)費(fèi)：
[1] 國家自然科學(xué)基金面上項目，中藥苦蕎頭有效成分Tatariside F靶向MZF1/lncRNA HClnc1/ODC1通路抗肝癌的分子機(jī)制研究，2022/01-2025/12，55萬元，在研，主持
[2] 國家重點研發(fā)計劃子課題，三種小血管病“異病同證”物質(zhì)基礎(chǔ)及復(fù)方“異病同治”藥理作用研究，2019/12-2022/06，216萬元，結(jié)題，主持
[3] 國家自然科學(xué)基金面上項目，基于細(xì)胞熱轉(zhuǎn)移分析技術(shù)的蔓荊呋喃誘導(dǎo)宮頸癌細(xì)胞凋亡分子靶點研究，2018/01-2021/12，55萬元，結(jié)題，主持
[4] 上海市科委科技創(chuàng)新行動計劃項目，中藥六類新藥冬柏通淋顆粒的臨床前研究，2015/07-2018/09，120萬元，結(jié)題，主持
[5] 上海市科委科技創(chuàng)新行動計劃項目，組分中藥祛瘢靈治療增生性瘢痕的成藥性研究，2015/07-2018/09，50萬元，結(jié)題，主持
[6] 浦東新區(qū)領(lǐng)先人才項目，PWR12015-05，蔓荊呋喃誘導(dǎo)宮頸癌細(xì)胞凋亡的分子靶點研究，2016/01-2019/12，60萬元，結(jié)題，主持
[7] 浦東新區(qū)科委項目，PKJ2015-Y13，卵巢癌分子診斷標(biāo)志物的篩選研究，2015/08-2018/07，28萬元，結(jié)題，主持
3. 第一/通訊作者代表性論文(近5年)
[1] Qiu-Ping Liu, Yu-Ying Chen, Pei An, Khalid Rahman, Xin Luan*, Hong Zhang*. Natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents. Phytomedicine, 2023, 109: 154612. (IF=6.656)
[2] Hong-Xuan Yang, Qiu-Ping Liu, Yan-Xi Zhou, Yu-Ying Chen, Pei An, Yi-Zhuo Xing, Lei Zhang*, Min Jia* and Hong Zhang*. Forsythiasides: A Review of the Pharmacological Effects. Frontiers in Cardiovascular Medicine, 2022, 9:971491. (IF=5.846)
[3] Qiu-Ping Liu?, Yu-Ying Chen?, Yuan-Yuan Yu?, Pei An, Yi-Zhuo Xing, Hong-Xuan Yang, Yin-Jian Zhang, Lei Zhang*, Xin Luan*, Hong Zhang*. Bie-Jia-Ruan-Mai-Tang, a Chinese medicine formula, inhibits retinal neovascularization in diabetic mice through inducing the apoptosis of retinal vascular endothelial cells. Frontiers in Cardiovascular Medicine, 2022, 9: 959298. (IF=5.846)
[4] Wen-Qing Li, Wen-Hao Liu, Die Qian, Jia Liu, Shi-Qiong Zhou, Lei Zhang, Wei Peng*, Li Su*, Hong Zhang*. Traditional Chinese medicine: an important source for discovering candidate agents against hepatic fibrosis. Frontiers in Pharmacology, 2022, 13: 962525. (IF=5.988)
[5] Pei An?, Dong Lu?, Lijun Zhang, Haiyue Lan, Hongxuan Yang, Guangbo Ge, Wei Liu, Weixing Shen, Xianting Ding, Dongxin Tang, Weidong Zhang, Xin Luan*, Haibo Cheng*, Hong Zhang*. Synergistic antitumor effects of compound-composed optimal formula from Aidi injection on hepatocellular carcinoma and colorectal cancer. Phytomedicine, 2022, 103:154231. (IF=6.656)
[6] Yu-Ying Chen, Qiu-Ping Liu, Pei An, Min Jia, Xin Luan*, Jian-Yuan Tang*, Hong Zhang*. Ginsenoside Rd: A promising natural neuroprotective agent. Phytomedicine, 2022, 95:153883. (IF=6.656)
[7] Qiu-Ping Liu?, Jia-Yi Lin?, Pei An, Yu-Ying Chen, Xin Luan*, Hong Zhang*. LncRNAs in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs. Biochemical Pharmacology, 2021, 193:114802. (IF=6.1)
[8] Pei An, Li-Jun Zhang, Wei Peng, Yu-Ying Chen, Qiu-Ping Liu, Xin Luan*, Hong Zhang*. Natural products are an important source for proteasome regulating agents. Phytomedicine, 2021, 93:153799. (IF=6.656)
[9] Yuan-Yuan Yu#, Qiu-Ping Liu#, Meng-Ting Li, Pei An, Yu-Ying Chen, Xin Luan*, Chao Lv*, Hong Zhang*. Hu-zhang-qing-mai-yin inhibits proliferation of human retinal microvascular endothelial cells exposed to high glucose. Frontiers in Pharmacology, 2021, 12: 732655. (IF=5.988)
[10] Gang Gong#, Yu-Li Shen#, Hai-Yue Lan#, Jin-Mei Jin, Pei An, Li-Jun Zhang, Li-Li Chen, Wei Peng*, Xin Luan*, Hong Zhang*. The Cyr61 is a potential target for rotundifuran, a natural labdane-type diterpenes from Vitex trifolia L., to trigger apoptosis of cervical cancer cells. Oxidative Medicine and Cellular Longevity, 2021, Article ID 6677687. (IF=7.31)
[11] Ting Yang, Yi-Xin Jiang, Ye Wu, Dong Lu, Rui Huang, Long-Ling Wang, Shi-Qi Wang, Yingyun Guan*, Hong Zhang*, Xin Luan*. Resibufogenin suppresses triple-negative breast cancer angiogenesis by blocking VEGFR2-mediated signaling pathway. Frontiers in Pharmacology, 2021, 682735. (IF=5.988)
[12] Mengting Li#, Jia Ke#, Yiqing Deng, Chunxiang Chen, Yichen Huang, Yuefeng Bian, Shufen Guo, Yang Wu, Hong Zhang*, Mingyuan Liu*, Yan Han*. The protective effect of liquiritin in hypoxia/reoxygenation-induced disruption on blood brain barrier. Frontiers in Pharmacology, 2021, 671783. (IF=5.988)
[13] Hai-Yue Lan#, Pei An#, Qiu-Ping Liu, Yu-Ying Chen, Yuan-Yuan Yu, Xin Luan*, Jian-Yuan Tang*, Hong Zhang*. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. Journal of Ethnopharmacology, 2021, 274, 114073. (IF=5.195)
[14] Gang Gong?, Ying-Yun Guan?, Zhong-Lin Zhang, Khalid Rahman, Su-Juan Wang, Shuang Zhou*, Xin Luan*, Hong Zhang*. Isorhamnetin: A review of pharmacological effects. Biomedicine & Pharmacotherapy, 2020, 128, 110301. (IF=7.419)
[15] Xin Luan?, Li-Jun Zhang?, Xiao-Qin Li, Khalid Rahman, Hong Zhang*, Hong-Zhuan Chen*, Wei-Dong Zhang*. Compound-based Chinese medicine formula: From discovery to compatibility mechanism. Journal of Ethnopharmacology, 2020, 254:112687. (IF=5.195)
[16] Xiao-Qin Li, Jian-Yong Zhu, Rong-Rong Pan, Yu-Li Shen, Khalid Rahmand, Chun-Yan Zhang, Li-Jun Zhang*, Xin Luan*, Hong Zhang*. Therapeutic effect of Dongbai-Tonglin-Fang, a Chinese herbal formula, on urinary tract infection in rat model. Journal of Ethnopharmacology, 2019 Sep 15;241:112028. doi: 10.1016/j.jep.2019.112028. (IF=5.195)
[17] Hong Zhang, Qing-Feng Tang, Meng-Yao Sun, Chun-Yan Zhang, Jian-Yong Zhu, Yu-Li Shen, Bin Zhao, Zhi-Yi Shao, Li-Jun Zhang*, Hong Zhang*. ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin. Cell Death & Disease, 2018, 9(9):916. (IF=9.685)